Muse bio secures $23M Series B financing led by Venrock
Muse bio, a privately-held company leading the development of next-generation genome engineering capabilities, today announced the completion of a $23 million Series B financing. The oversubscribed financing was led by Venrock and included investments from Foresite Capital and Paladin Capital as well as both Series A investors, NanoDimension and Spruce/MLS.
Accenture to Expand Proactive Cybersecurity Defense Services Capabilities with Acquisition of Endgame Federal Services Business
Accenture (NYSE: ACN) has entered into an agreement to acquire the U.S. federal government services business of Endgame Inc., a privately held endpoint detection and response (EDR) cybersecurity software company based in Arlington, VA. Endgame’s federal government...PhishMe Reports Explosive Growth: Annual Run Rate Approaches $50 Million
PhishMe Inc., the leading provider of human phishing defense solutions, today announced another year of record growth, with Annual Run Rate (ARR) approaching $50 million. PhishMe’s more than 300 employees now serve 1,200 enterprise customers world-wide to defend against cybercriminals, hacktivists and state-sponsored hackers.
ProtectWise Raises $25M in Additional Capital to Accelerate Market Adoption of Disruptive Cloud-Delivered Security Platform
ProtectWise, provider of the enterprise security platform that delivers pervasive visibility, automated threat detection and unlimited forensic exploration on demand, today announced it has closed a $25 million Series B round of funding. As a part of this round, the...White Ops Exposes Largest and Most Profitable Ad Fraud Bot Operation
White Ops, the leading provider of human verification services for the digital advertising market, announced today that its security researchers have exposed the most profitable and advanced ad fraud operation ever seen by the industry.